people have pain reportedly attributed to arthritis 1) . It results in 36 million working days lost annually in the UK and an es timated 115,000 hospital admissions 1) . Knee OA is additionally the most common form of OA causing disability in the UK. The symptomatic treatment of OA focuses mainly on physical thera py, analgesics, nonsteroidal antiinflammatory drugs (NSAIDs) and intraarticular injections of corticosteroids 2) . However, the sideeffects of NSAIDs and intraarticular steroid injections have directed the interest towards alternative forms of treatment, such as viscosupplementation with hyaluronic acid (HA) 3, 4) . HA has been shown to increase elasticity and reduce viscosity in high shear, as well as reduce elasticity and increase viscosity in low shear stress 57) . In addition to mechanical properties, experi mental studies have shown a chondroprotective effect attributed to antiprotease and antiapoptotic actions as well as an upregula tion of endogenous HA 8, 9) . Kim osteochondral defect healing in animal models treated with intra articular HA. Both native and crosslinked hyaluronan are being used for the treatment of human OA. Lower molecular weight preparations (e.g. Artzal, Fassverksamheten, Stockholm, Swe den) generally range in molecular weight from 0.5 to 1 million dalton, while the molecular weight of crosslinked preparations (e.g. SynviscOne, SanofiAventis, Ridgefield, NJ, USA) is consid erably higher at 6,000 kilodaltons (kDa) 11, 12) . New evidence has recently also demonstrated the relative importance of molecular weight and the concentration of hyaluronan for its efficacy 13) . Even though previous trials have reported that intraarticular hyaluronan is a safe and welltolerated treatment, controversies remain surrounding choice of products and patient selection 1417) . In addition, there has been paucity of studies demonstrating lon ger duration of clinical benefit following viscosupplementation in the treatment of knee OA 18) . Consequently, conditional recom mendations have been put forward in relation to its utilisation according to a variety of specialist societies such as Osteoarthritis Research Society International, the European League Against Rheumatism and the American College of Rheumatology, and the American Academy of Orthopedic Surgeons 19) . Reviewed recommendations also suggest attention to patient selection due to different phenotypes of OA 19) . A retrospective observational analysis of a single centre single therapeutic clinical series was conducted in order to evaluate longterm results following intraarticular injections of high mo lecular weight hyaluronic preparation hylan GF20 (SynviscOne) in selected patients with symptomatic knee OA. The objective of the study was to report the fiveyear therapeutic effect survivor ship taking knee arthroplasty and any other surgical intervention as endpoints.
Materials and Methods
From 2010 to 2011 a total of 77 consecutive patients received SynviscOne knee intraarticular injection carried out in a spe cialist orthopaedic knee outpatient clinic. Selection criteria were derived from a multidisciplinary management algorithm. All patients were treated with initial medical management of OA, which includes weight loss, analgesia and activity modification advice. Inclusion criteria consisted of symptomatic knee OA and radiologically confirmed disease on standard weight bearing knee radiographic views. All patients included had confirmed ar thritic symptoms following clinical evaluation in the knee clinic. In addition to those having radiographs confirming tibiofemoral compartment location of disease, patients not medically fit for surgery, considered too young for arthroplasty, or patients whose occupation would have precluded them from having an arthro plasty were included in the intervention protocol. Using data from our National Joint Replacement Registry (NJR), the catego ries tooyoung and notfit for surgery were respectively bench marked at <40 years and American Society of Anaesthesiologists grade 4 (severe systemic disease that is a constant threat to life). The latter categories both represented an outlying cohort of <1% on the NJR database 20) . Exclusion criteria consisted of patients with predominantly mechanical symptoms and well preserved joint who required further imaging in the form of magnetic resonance imaging and progression to arthroscopic treatment where indicated. Acute cases of flareup were treated with aspiration and injection of intraarticular corticosteroid and subsequently managed accord ing to the management algorithm outlined in Fig. 1 . In addition, patients with a predominantly patellofemoral location of disease were considered for physiotherapy or patellofemoral arthroplasty depending on the extent of functional loss and severity of de generative changes. Rheumatoid arthritis or other inflammatory joint diseases were excluded. Furthermore, patients were not included if they had a known allergy to any substance related to the injection. The study analysis included only patients who were treated with SynviscOne from the outset.
The HA injection used was hylan GF20 with a molecular weight of 6,000 kDa (SanofiAventis). The technique for injection followed a standardised method of aseptic no touch technique. The skin is prepared with alcoholic chlorhexidine and allowed to air dry. The knee joint is positioned in extension and the injec tion portal follows the patellofemoral compartment to allow easy access to the anterior portion of the joint space. The injection is carried out using a prefilled sterile packed syringe and 'white' hypodermic needle. The injection site is covered with a simple dry dressing and the patient is allowed to mobilise fully and discharged back to primary care. Repeat of injection was not rou tinely carried out unless patients experienced symptomatic ben efit for a minimum period of nine months following the initial injection. As per our local protocol, if there was no response or limited response, patients needed to be referred back to second ary care to consider other surgical interventions.
Baseline characteristics and diagnostic data were recorded at the initial visit and patients were entered into a prospectively collect ed database for evaluation of clinical outcomes at one year and at five years after the initial injection. The primary efficacy pa rameter at one year and during the total fiveyear duration of the study was defined as absence of subsequent referral to secondary Knee Surg Relat Res, Vol. 29, No. 2, Jun. 2017 131 care other than for repeat SynviscOne injection. These patients were defined as responders to the injection therapeutic effect if they had not returned for a secondary intervention excluding re peat SynviscOne injection. The parameters were recorded from the hospital electronic medical record. If no hospital records were identified, clinical data was checked with the primary care general practice in case the patients had represented with knee symptoms and/or referred to another centre. The secondary ef ficacy parameter consisted of time to clinical failure as defined by the need for secondary treatment for the study knee excluding repeat SynviscOne injection. Secondary interventions included arthroscopic procedures or arthroplasty during the study period as well as patients awaiting arthroplasty surgery at the end of the fiveyear study period. Similarly, these parameters were recorded from the trust electronic medical record and checked with the primary care practice in case patients were referred for treatment in another centre in order to reduce errors and loss of cases. All patients who received the initial intervention were accounted for at five years of followup. Finally, duration of clinical benefit was measured using survival analysis taking arthroplasty and all sec ondary interventions as endpoint results. Safety of injections was evaluated by the presence of any adverse reaction immediately after the treatment and the presence of any subsequent complica tions related to the injection.
In terms of ethical provisions, the study was conducted in ac cordance with the principles of good clinical practice and in accordance with the declaration of Helsinki, and was approved by the trust audit department (ID/647). Approval for product 
results
A total of 77 consecutive patients (82 knees) were eligible for the intervention and had clinical outcome measures recorded and followup of outcomes at one year and five years following initial injection of SynviscOne. The cohort comprised 36 male (47%) and 41 female (53%) patients. The mean age at the time of index intervention was 58 years (standard deviation [SD], 11.9; range, 32 to 88 years) (95% confidence interval, 51.5-73.2). Multivariate regression analyses of the baseline characteristics and potential confounding factors were carried out. There was no significant relationship between gender and clinical outcomes in the form of secondary interventions (p=0.41). Mean ages per intervention group were: 58.8 years (SD, 13) in the arthroplasty group; 57.5 years (SD, 14.9) among patients who had no further interventions; and 57.9 years (SD, 9.4) among patients who had a repeat injection. There was no significant difference in mean age in the different clinical outcome groups at fiveyear followup for any subsequent intervention (p=0.72) and for all interventions grouped together (p=0.64).
At one year, 71 (87%) of knees, which received the intervention, responded to treatment and only 8 (10%) were listed for arthro plasty due to persistence of symptoms. Within the responders, a total of 53 (65%) were reviewed and 18 (22%) were discharged. According to our protocol, these cases were considered respond ers in terms of primary therapeutic efficacy. At fiveyear follow up, 41 (50%) of knees, which received the initial injection, were classed as responders. These included 32 (39%) asymptomatic and 9 (11%) who required a repeat of one injection only as per protocol. All cases which received a repeat injection did so within the time frame of six to nine months postulated in the original treatment plan. During the fiveyear period, 26 (31%) required arthroplasty, either total or unicompartmental. Clinical outcomes are outlined in Table 1 . Within secondary surgical procedures carried out during the study period, there was one arthroscopic microfracture at one year and two arthroscopic debridements of meniscal tears at five years due to development of mechani cal symptoms. There were no records of adverse reactions to the injections reported during the study period. One patient was not available for followup at one year but was later identified and reviewed at five years. This particular case did not require further intervention and remained asymptomatic at five years. KaplanMeier failuretime curves were used to analyse the cumulative probability of patients not requiring additional treat ment for their study knee during the followup period. The analysis demonstrated 67% survival at 5 years with arthroplasty as the endpoint and 58% survival at 5 years with all secondary interventions, excluding repeat SynviscOne injection, as the endpoint (Tables 2 and 3 , Figs. 2 and 3) . Throughout the five year study period, there were no adverse reaction or longterm complications related to the injection of HA.
discussion
The painrelieving mechanism of intraarticular injections of HA is yet to be fully elucidated. It has been suggested that the injections may stimulate the synthesis of endogenous HA and act as a scavenger, reducing the amount of inflammatory degrada tion products in the joint. Furthermore, the viscoelastic and anti inflammatory functions of the synovial fluid may be improved by the treatment. The utilisation of this treatment has been closely monitored within our unit. The present study constitutes a de tailed longterm analysis of consecutive patients treated by a mul tidisciplinary team and followed up for five years. The principal findings were the longterm efficacy and safety of intraarticular injections of hyaluronic preparation (SynviscOne/hylan GF 20) for patients with symptomatic knee OA. The present study demonstrates a significantly longer duration of clinical benefit. One third of patients required arthroplasty surgery and over half of the patients did not require any further secondary intervention at five years of followup. In a pragmatic setting, our primary and secondary efficacy parameters support the use of this interven tion in adequately selected patients with purely arthritic symp toms, who are either 'not ready' or 'not willing' to undergo joint replacement surgery.
The subject of HA injection in the treatment of OA has been vastly studied. Within the literature a large number of clinical tri als, systematic reviews and metaanalyses had sought to answer the question of HA injection efficacy and how it compares to other treatment modalities. Wang et al. 15 ) conducted a metaanal ysis, which confirmed the therapeutic efficacy and safety of intra articular injection of HA for the treatment of OA of the knee. Bellamy et al. 16 ) demonstrated a therapeutic effect superior to pla cebo but not significantly different to NSAIDs or intraarticular corticosteroid injections. This metaanalysis, which included 76 trials looking at 20 different HA products, echoes our results of sustained efficacy over a long period of time in adequately select ed patients. Lo et al. 17) demonstrated a moderate therapeutic ef fect when compared to placebo in a metaanalysis of 22 selected . Nevertheless, publication bias and heterogene ity of the studies included mitigated these results. Similar results were widely reported in the international literature, with added evidence of favourable costeffectiveness in the utilisation of HA injection for symptomatic arthritic "dry" knees 21, 22) . A more re cent metaanalysis reported similar methodological limitations. The authors suggested a significant association between cross linked hyaluronan and longterm results, yet not beyond the two year mark 18) . A recent randomised controlled trial compared hylan GF20 single shot injection with corticosteroid injection. The authors reported that both groups had similar improvement in pain, knee function, and range of motion during the 6month followup (p<0.001) 23, 24) . In contrast, an earlier study by Anand et al. 25) showed that multipledose injections of HA when given in advanced arthritis lasted for up to three years and delayed the need for knee arthroplasty in 58% of the cases. The scope of our clinical series was not to replicate the results previously published in the literature. Our present study adds valuable observations, which can easily be applied in other insti tutions. In adequately selected patients with knee OA who are not medically fit or ready for arthroplasty according to the criteria defined above and reports from the NJR database 20) , SynviscOne injection can constitute a satisfactory treatment modality even in the longterm. Patient selection remains a difficult challenge. We demonstrated results following the implementation of a rigorous management algorithm. We believe that a more liberal approach could have attenuated the overall therapeutic effect within this patient population. Factors predicting longterm efficacy of in jection have been previously reported. Conrozier et al. 26) reported results at 14 months with a 78% global therapeutic effect lasting up to that point. Factors significantly associated with a favourable response in their series were: moderate effusion, injection lateral to the patella, joint space loss in a single compartment, and radio logical meniscal calcinosis 26) . All studies investigating the efficacy of HA injections appear to share numerous and recurring limitations such as: sample size, clinical environment, outcome measures, disease duration, ra diological grade, and rescue medications. Even in the most con trolled environment, such factors will inadvertently mitigate the interpretation of evidence reported. The present study followed a pragmatic approach, reflecting a normal clinical environment to which patients are exposed. The principal limitation of the present study was therefore the lack of filter for all possible con founding factors, which could influence the results of treatment. Nevertheless, it is the authors' viewpoint that this contributes to evidence for the efficacy of HA injection within this heteroge neous patient population. It is often difficult to translate evidence extracted from the very tightly regulated environment of ran domised controlled studies and apply to the realism of everyday practice. It can be attributed to the very fact that outside the controlled environment represented in such studies, patients are exposed to numerous confounding factors. This is especially true for knee OA, a condition with a complex natural history. Con sequently, our results characterise a pragmatic approach to the question. The efficacy parameters reported above may have been heavily influenced by external factors. However, when patients are adequately selected, such approach adds external validity to the results reported in our study. Instead of becoming a single therapeutic answer, the longterm results presently reported can become an addition in the armamentarium of the orthopaedic surgeon when discussing treatment options with their patients.
conclusions
The majority of patients with symptomatic knee OA who were treated with hylan GF20 injection using our protocol showed clinical improvement. Our treatment algorithm incorporating a single product SynviscOne injection demonstrated longterm effect when arthroplasty and any other surgical intervention were measured as endpoints. This therapeutic series demonstrates a significantly longer duration of clinical benefit for SynviscOne injection compared to previous studies. Only a third of patients required arthroplasty surgery and over half of the patients did not require any further surgical intervention at fiveyear follow up. Results are echoed in the literature, most likely attributed to molecular weight of preparation and improved patient selection. These results can suggest a notion of an ideal delay therapeutic strategy for patients not ready to receive an arthroplasty. The present study should also pave the way for further research with attention to product and patient selection, in order to determine whether such a pragmatic approach can be widely implemented.
